VYNE logo.jpg
VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
January 19, 2022 08:00 ET | VYNE Therapeutics Inc.
Systemic bioavailability of JAK inhibitor (tofacitinib) and S1P receptor modulator (fingolimod) in topical formulation substantially lower compared to oral equivalents Mean Cmax of tofacitinib...
VYNE logo.jpg
VYNE Therapeutics Divests Topical Minocycline Assets
January 13, 2022 07:00 ET | VYNE Therapeutics Inc.
Transaction includes cash payments of $25 million and potential milestones of up to $450 million Sale aligns with VYNE’s strategic plan; proceeds will be used to fund development of Company’s...
VYNE logo.jpg
VYNE Therapeutics to Participate at the LifeSci Partners 11th Annual Corporate Access Event
January 03, 2022 08:00 ET | VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Jan. 03, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that management will participate in one-on-one investor meetings...
VYNE logo.jpg
VYNE Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 18, 2021 08:00 ET | VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at...
VYNE logo.jpg
VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
November 10, 2021 07:30 ET | VYNE Therapeutics Inc.
Lead BET Inhibitor Candidate, VYN201, Demonstrates Potent Anti-Inflammatory Effect in Preclinical Studies VYN201 Expected to Enter Clinic in 2022 Phase 2a Results for FMX114 in Mild-to-Moderate...
VYNE logo.jpg
Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass and Overall Skin Repair Outcomes in Preclinical Study
November 04, 2021 08:00 ET | VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced preclinical data from a validated animal study showing that its...
VYNE logo.jpg
VYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021
October 28, 2021 08:00 ET | VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third quarter...
VYNE logo.jpg
Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflammatory Cytokines in Preclinical Studies
October 26, 2021 08:00 ET | VYNE Therapeutics Inc.
VYN201 exhibits anti-inflammatory effect in preclinical data similar to a super-potent glucocorticosteroidVYN201 appeared well-tolerated in mice, as seen through animal body weight and skin...
VYNE logo.jpg
VYNE Therapeutics Announces Formation of Scientific Advisory Board
October 21, 2021 08:00 ET | VYNE Therapeutics Inc.
Renowned Experts to Support VYNE’s Strategy of Developing Novel Treatments for Immunological and Inflammatory diseases SAB to Help Guide Clinical Development of VYNE’s BET Inhibitor Drug Candidates...
VYNE logo.jpg
VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
October 19, 2021 08:00 ET | VYNE Therapeutics Inc.
Important milestone achieved as part of the Company’s new corporate strategy to develop treatments for immuno-inflammatory diseases Topline results anticipated in early Q1 2022 BRIDGEWATER,...